Intraepidermal carcinoma

Author: Honorary Associate Profesor Amanda Oakley, Hamilton, New Zealand, 1997. Updated December 2015.

Intraepidermal squamous cell carcinoma (SCC) is a common superficial form of skin cancer. It is also known as Bowen disease, intraepidermal carcinoma (IEC) and carcinoma in situ of the skin.

Intraepidermal SCC is derived from squamous cells, the flat epidermal cells that make keratin—the horny protein that makes up skin, hair and nails. ‘Intraepidermal’ and ‘in situ’ mean the malignant cells are confined to cell of origin, ie, the epidermis.

Who gets intraepidermal squamous cell carcinoma?

Risk factors for intraepidermal SCC include:

Up to 50% of patients with intraepidermal SCC have other keratinocytic skin cancers, mainly basal cell carcinoma.

What causes intraepidermal SCC?

Ultraviolet radiation (UV) is the main cause of intraepidermal SCC. It damages the skin cell nucleic acids (DNA), resulting in a mutant clone of the gene p53. This sets off uncontrolled growth of the skin cells. UV also suppresses the immune response, preventing recovery from damage.

What are the clinical features of intraepidermal SCC?

Intraepidermal SCC presents as one or more irregular scaly plaques of up to several centimetres in diameter. They are most often red but may also be pigmented.

Although intraepidermal SCC may arise on any area of skin, it is most often diagnosed on sun-exposed sites of the ears, face, hands and lower legs. When there are multiple plaques, distribution is not symmetrical (unlike psoriasis).

Rarely, intraepidermal SCC may start to grow under a nail, when it results in a red streak (erythronychia) that later may destroy the nail plate.

More images of intraepidermal SCC ...

Intraepidermal SCC may start to grow under a nail, when it results in a red streak (erythronychia) that later may destroy the nail plate.

Complications of intraepidermal squamous cell carcinoma

Invasive SCC arises in about 5% of intraepidermal SCC lesions.

How is intraepidermal squamous cell carcinoma diagnosed?

Intraepidermal SCC is often recognised clinically because of an irregular scaly plaque. Dermatoscopy is supportive if it reveals crops of rounded or coiled blood vessels. Diagnosis may be confirmed by biopsy; histology reveals full thickness dysplasia of the epidermis.

What is the treatment for intraepidermal SCC?

As intraepidermal SCC is confined to the surface of the skin, there are various ways to remove it. Recurrence rates are high, whatever method is used, particularly in immune suppressed patients.


As the risk of invasive SCC is low, it may not be necessary to remove all lesions particularly in elderly patients. Keratolytic emollients, eg containing urea or salicylic acid, may be sufficient to improve symptoms.


Solitary lesions can be cut out, and the defect repaired by stitching it up. Excision is necessary if there is suspicion of invasive SCC.

Superficial skin surgery

Superficial skin surgery refers to shave, curettage and electrosurgery, and is a good choice for solitary or few hyperkeratotic lesions. The lesion is sliced off or scraped out, then the base is cauterised. Dressings are applied to the open wound to encourage moist wound healing over the next few weeks.


Cryotherapy means removing a lesion by freezing it, usually with liquid nitrogen. Moderately aggressive cryotherapy is suitable for multiple, small, flat patches of intraepidermal SCC. It leaves a permanent white mark at the site of treatment.

Fluorouracil cream

5-fluorouracil cream contains a cytotoxic agent and can be applied to multiple lesions. The cream may be applied to intraepidermal SCC for 4 weeks, and repeated if necessary. It causes a vigorous skin reaction that may ulcerate.

Imiquimod cream

Imiquimod cream is an immune response modifier used off-licence to treat intraepidermal SCC. It is applied 3–5 times weekly for 4–16 weeks and causes an inflammatory reaction.

Photodynamic therapy

Photodynamic therapy (PDT) refers to treatment with a photosensitiser (a porphyrin chemical) that is applied to the affected area prior to exposing it to a strong source of visible light. The treated area develops an inflammatory reaction and then heals over a couple of weeks or so. The best studied, methyl levulinate cream PDT used off licence, provides high cure rates for intraepidermal SCC on the face or lower legs, with excellent cosmetic results. The main disadvantage is the pain experienced by many patients during treatment.


Other treatments occasionally used in the treatment of intraepidermal SCC include:

How can intraepidermal SCC be prevented?

Very careful sun protection at any time of life can reduce the number of intraepidermal SCCs. This is particularly important for ageing, sun-damaged, white skin; and in patients that are immunosuppressed.

What is the outlook for intraepidermal SCC?

Intraepidermal SCC may recur months or years after treatment. The same treatment can be repeated or another method used.

Patients that have been treated for intraepidermal SCC are at risk of developing new lesions of intraepidermal SCC. They are also at increased risk of other skin cancers, especially squamous cell carcinoma, basal cell carcinoma and melanoma.

Related information

Make a donation

Donate Today!